You are here

Our science / Clinical Trials / Find a Trial / NCT00938015

Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis

Back to Search Print Save as PDF Bookmark Trial

NCT00938015

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Leuven, , 3000 Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Active erosive psoriatic arthritis of poly-articular type or active erosive or with
joint space narrowing psoriatic arthritis of oligo-articular type

- At least 18 years old

- Have fulfilled reimbursement criteria for Enbrel in psoriatic arthritis of
poly-articular type or oligo-articular type

- Physician decides to prescribe Enbrel or patient is already on Enbrel

- Give written informed consent at time of inclusion to study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00938015
Pfizer
Completed
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Knee Osteoarthritis
A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
NCT00650624
All Genders
20+
Years
Multiple Sites
Osteoarthritis
Study Evaluating AGG-523 in Subjects With Osteoarthritis
NCT00427687
All Genders
40+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
NCT02709486
All Genders
18+
Years
Multiple Sites
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
A Post-Marketing Surveillance For Safety And Adherence To Treatment Of Enbrel In Adults With Psoriatic Arthritis In Belgium
The aim of this study is to evaluate if the data obtained in controlled clinical trials are confirmed when Enbrel is used in usual clinical practice in Belgium according to local reimbursement criteria.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
rheumatology centers
Arthritis, Psoriatic
Other: Questionnaire
This is a non-interventional study
  • PsA Patients (New)
    New patients
    Intervention: Other: Questionnaire
  • PsA Patients
    CU patients
    Intervention: Other: Questionnaire
de Vlam K, Boone C, The Prove Study Group A. Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study). Clin Exp Rheumatol. 2015 Sep-Oct;33(5):624-31. Epub 2015 Jul 23.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
303
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Active erosive psoriatic arthritis of poly-articular type or active erosive or with joint space narrowing psoriatic arthritis of oligo-articular type
  • At least 18 years old
  • Have fulfilled reimbursement criteria for Enbrel in psoriatic arthritis of poly-articular type or oligo-articular type
  • Physician decides to prescribe Enbrel or patient is already on Enbrel
  • Give written informed consent at time of inclusion to study

Exclusion Criteria:
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT00938015
0881A-101698
B1801107
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now